Introduction. Mutations in a GBA1 gene, which encodes a lysosomal enzyme called glucocerebrosidase (GCase), are the most common genetic risk factor for Parkinson's disease (PD). The pathogenesis of PD results from the death of dopaminergic neurons in the substantia nigra of the brain, which is associated with the aggregation of α-synuclein protein. However, not all GBA1 mutation carriers develop PD during their lifetime. The aim of this study was to evaluate GCase activity and α-synuclein levels in CD45+ blood cells of patients with PD associated with GBA1 mutations (GBА1-PD), asymptomatic carriers of GBA1 mutations (GBА1-carriers), and patients with sporadic PD (sPD), as well as correlation between the study parameters in the study groups. Materials and methods. The study included patients with GBА1-PD (n = 25) and sPD (n = 147), and GBА1-carriers (n = 16). A control group included healthy volunteers (n = 154). The level of α-synuclein in CD45+ cells was measured by enzyme-linked immunosorbent assay, and GCase activity in dried blood spots was detected by high-performance liquid chromatography with tandem mass spectrometry. Results. Increased level of α-synuclein protein was detected in CD45+ blood cells of patients with GBA1-PD, sPD, and GBA1-carriers compared to controls (p = 0.0043; p = 0.0002; p = 0.032, respectively). Decreased GCase activity was reported in GBA1-PD patients and GBA1-carriers compared to sPD patients (p = 0.0003; p = 0.003, respectively) and controls (p 0.0001; p 0.0001, respectively). However, negative correlation between α-synuclein levels and GCase activity was observed only in GBA1-PD patients, but not in GBA1-carriers. Conclusion. Our data suggest a possible functional relationship between the activity of GCase and the metabolism of α-synuclein in PD associated with GBA1 mutations.
25 October 2021 in The Scientific Notes of the Pavlov University
Нemimasticatory spasm (HMS) is a rare disorder of the nervous system, in which there are unilateral, violent spasms of the masticatory muscles innervated by the motor portion of the trigeminal nerve. The causes of HMS remain largely unexplored, but microvascular compression is most likely. Anticonvulsants, surgical treatment and botulinum therapy can be applied for the treatment of HMS.We presented a clinical case of HMS in a 38-year-old woman who had been suffering from this disease for 18 years. The diagnosis of HMS was established only 10 years after the first visit to the doctor. Spasms could occur up to several hundred times a day with a duration up to 15 seconds. The magnetic resonance imaging allowed to exclude neurovascular conflict. Electroneuromyography revealed axonal lesion of the right trigeminal motor root and spontaneous activity in the right masseter muscle. Anticonvulsant treatment was ineffective. The patient received botulinum therapy with a good treatment result.
16 May 2022 in The Scientific Notes of the Pavlov University
The objective of the study was to validate our previous results obtained during the transcriptome analysis of the primary culture of peripheral blood macrophages in patients with Parkinson's disease associated with mutations in the GBA gene (GBA-PD) in that reduced expression of the neurogenesis genes EGR1 (early growth response protein 1), NR4A2 (nuclear receptor 4A2), JUNB (transcription factor jun-B) in patients with GBA-PD.Methods and materials. The study included 14 patients with GBA-PD, 15 GBA-carriers, 30 patients with Parkinson's disease (PD) and 44 persons of the control group. The assessment of relative mRNA level of neurogenesis genes EGR1, NR4A2, JUNB in peripheral blood mononuclear cells were carried out by real-time quantitative polymerase chain reaction (PCR) using TaqMan fluorescent probes or EvaGreen fluorescent DNA dye.Results. Relative mRNA level of the JUNB gene in peripheral blood mononuclears was decreased in the group of patients with GBA-PD compared to controls (p=0.034). We found out that the relative mRNA level of the NR4A2 gene in peripheral blood mononuclears was increased in the group of patients with GBA-carriers compared to GBA-PD, patients with PD and controls (p=0.0029, p=0.00045, p=0.0024 respectively). There were no statistically significant differences in the mRNA level of the EGR1 gene between all the study groups (p>0.05).Conclusion. GBA-PD is characterized by reduced expression of the JUNB gene compared to control and of the NR4A2 gene compared to GBA-carriers.
20 November 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Traditionally, Parkinson’s disease is considered a disease of old age. However, in 5—10% of patients, it is detected before the age of 40 years. This age is included in the childbearing period. Beliefs of the unwantedness of pregnancy, its impossibility, or the high risks associated with delivery are common. However, data on the course of pregnancy are limited and conflicting. Therefore, the development of evidence-based recommendations is an urgent task. In recent years, new data have been obtained regarding the course of pregnancy in patients with Parkinson’s disease, which are presented in this article.
7 June 2025 in The Scientific Notes of the Pavlov University
Introduction. The accumulation of neurotoxic forms of alpha-synuclein protein in brain tissues plays a key role in the pathogenesis of Parkinson’s disease (PD). In this case, lysosome dysfunction is considered as one of the possible causes of alpha-synuclein accumulation in cells. The commonality of the pathogenesis of PD and lysosomal storage diseases (LSD) is discussed. Mutations in two genes, GBA1 and SMPD1, leading to the development of Gaucher and Niemann-Pick А/В diseases, respectively, are associated with a high risk of PD development. The contribution of rare variants in other LSD genes is discussed.The objective of this study was to assess the association of rare gene variants of lysosomal storage diseases and Parkinson’s disease in the North-Western region of Russia.Methods and materials. An analysis of data obtained as a result of massive parallel sequencing of 44 genes associated with lysosomal storage diseases was carried out in 496 patients with PD and 401 individuals in the control group.Results.The study revealed a statistically significant difference in the frequency of occurrence of pathogenic and likely pathogenic variants of the LSD genes among patients with PD compared to the control group (p<0.05). An association of pathogenic and opportunistic rare variants of the ARSA and SGSH genes with an increased risk of PD development was revealed.Conclusion. The obtained data confirm the role of rare variants of the LSD genes in PD pathogenesis.